

Special Issue

Next-Generation Recombinant Vaccines for Veterinary Infectious Diseases

Message from the Guest Editors

Recombinant vaccines have transformed veterinary medicine by enabling precise delivery of pathogen-specific antigens through advanced genetic and protein engineering technologies. Platforms such as viral vectors, subunit vaccines, DNA vaccines, and emerging mRNA-based systems, along with nanoparticle antigen display, offer enhanced safety, immunogenicity, and DIVA compatibility. These approaches are increasingly applied to control economically significant and zoonotic diseases in livestock, poultry, and companion animals. Despite substantial progress, challenges remain in delivery optimization, cost-effectiveness, and achieving consistent immune responses across species. Continued innovation in recombinant and mRNA vaccine design is required for improving global animal health, productivity, and food security. We welcome submissions of original research articles, reviews, and perspectives related to (but not limited to) this Special Issue.

Guest Editors

Dr. Ravendra P. Chauhan

Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk, ul. Abrahamowa 58, 80-307 Gdansk, Poland

Prof. Dr. Boguslaw Szewczyk

Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk, Abrahamowa 58, 80-307 Gdansk, Poland

Deadline for manuscript submissions

15 April 2027



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/279311

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).